Skip to content

Medical emergency? What to do

Pfizer receives FDA approval for Eraxis to treat candidemia

3-RXPublished February 22, 20063 min read

Key points

  • Pfizer said today that Eraxis (anidulafungin) has been approved by the U.S.
  • In the U.S., patients with candidemia on average spend an additional 10 days in the hospital at an average increase in hospital charges of about $39,000 per patient.
  • Eraxis, an antifungal medicine of the echinocandin class, also was approved by the FDA to treat two additional infections caused by the Candida fungus-peritonitis and intra-abdominal abscesses -- as well as esophageal candidiasis, a fungal infection of the esophagus.
  • Eraxis is the only medicine that has demonstrated improved efficacy versus fluconazole in a pivotal clinical trial for the treatment of candidemia.

Pfizer said today that Eraxis (anidulafungin) has been approved by the U.S. Food and Drug Administration to treat candidemia, a potentially life-threatening bloodstream infection. Candidemia is the most deadly of the common hospital-acquired bloodstream infections, with a mortality rate of approximately 40 percent.

In the United States, candidemia affects approximately one in 5,000 people, resulting in an estimated 60,000 cases each year. "Bloodstream infections such as candidemia can spread quickly and are very dangerous, especially for patients with weakened immune systems," said Dr. Joseph Feczko, Pfizer's chief medical officer. "Physicians treating these seriously ill patients now have an important new treatment in Eraxis."

Patients at high risk for candidemia and systemic candidiasis (Candida infection that spreads throughout the body) include those with compromised immune systems, stem-cell and organ-transplant recipients, patients on chemotherapy, patients with catheters, critically ill patients in intensive care units, surgical patients and patients on prolonged antibiotic therapy. In the U.S., patients with candidemia on average spend an additional 10 days in the hospital at an average increase in hospital charges of about $39,000 per patient.

"In the clinical trial setting, patients taking Eraxis for the treatment of candidemia had improved efficacy versus those taking fluconazole, making Eraxis an important addition to the options in antifungal treatment," said Dr. Annette Reboli, head of the Division of Infectious Diseases at Cooper University Hospital in Camden, New Jersey, and lead clinical investigator. "In addition, Eraxis has been shown to have a safety profile comparable to fluconazole and to be compatible with many medicines commonly used by patients with candidemia who have other serious health complications."

Eraxis, an antifungal medicine of the echinocandin class, also was approved by the FDA to treat two additional infections caused by the Candida fungus-peritonitis and intra-abdominal abscesses -- as well as esophageal candidiasis, a fungal infection of the esophagus.

Eraxis builds upon Pfizer's extraordinary strength in medicines for the treatment of infectious diseases, particularly antifungal treatments. Pfizer's Diflucan(R) (fluconazole) has been the longstanding gold standard treatment for candidemia and other fungal infections, especially opportunistic infections in HIV/AIDS patients. Pfizer's Vfend(R) (voriconazole), also a product of innovative Pfizer research, is a treatment for serious mold and yeast infections. Both Diflucan and Vfend are azole-type antifungal treatments.

Eraxis is the only medicine that has demonstrated improved efficacy versus fluconazole in a pivotal clinical trial for the treatment of candidemia. Eraxis was added to the company's antifungal portfolio through the acquisition of Vicuron in September 2005.

http://www.pfizer.com/

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.